Amarin up 3% premarket on draft ICER report confirming Vascepa value Jul. 24, 2019 9:07 AM ET|About: Amarin Corporation plc (AMRN)|By: Douglas W. House, SA News Editor Amarin (NASDAQ:AMRN) perks up 3% premarket on light volume on the heels of a draft report from the non-profit Institute for Clinical and Economic Review (ICER) concluding that Vascepa (icosapent ethyl) and Johnson & Johnson's (NYSE:JNJ) blood thinner Xarelto (rivaroxaban) provide clinical benefit, reduce cardiovascular risk and "fall below commonly cited thresholds for cost-effectiveness." In other words, the products are priced appropriately for the value delivered. JNJ is off a fraction premarket. See all stocks on the move ยป |
|
aus der Diskussion: | Amarin - The Science Of Lipid Therapy |
Autor (Datum des Eintrages): | Magnetfeldfredy (24.07.19 15:18:28) |
Beitrag: | 545 von 1,840 (ID:61095871) |
Alle Angaben ohne Gewähr © wallstreetONLINE |